PANACEABIO2024-10-012024-12-31 PANACEABIO2024-10-012024-12-31 PANACEABIO2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member PANACEABIO2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member PANACEABIO2024-12-31 PANACEABIO2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue01Member PANACEABIO2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue02Member PANACEABIO2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue01Member PANACEABIO2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue02Member PANACEABIO2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults01Member PANACEABIO2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults02Member PANACEABIO2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults01Member PANACEABIO2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults02Member PANACEABIO2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets01Member PANACEABIO2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets02Member PANACEABIO2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member PANACEABIO2024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member PANACEABIO2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member PANACEABIO2024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 531349 PANACEABIO NOTLISTED Panacea Biotec Limited Equity 2024-04-01 2025-03-31 2025-02-14 2025-01-31 INR Lakhs Third quarter 14:00:00 16:52:00 2025-02-14 2025-02-14 Not applicable Multi segment 2024-10-01 2024-12-31 Unaudited Consolidated 1634900000.00 36200000.00 1671100000.00 487400000.00 1500000.00 136600000.00 429800000.00 9900000.00 89800000.00 500000000.00 1655000000.00 16100000.00 27700000.00 43800000.00 0.00 -600000.00 -600000.00 0.00 44400000.00 0.00 0.00 0.00 0.00 44400000.00 -800000.00 43600000.00 45200000.00 -800000.00 44400000.00 -800000.00 61300000.00 1 0.74 0.74 0.00 0.00 0.74 0.74 Notes: 1. The financial results for the quarter and nine months ended December 31, 2024 were reviewed by the Audit Committee and recommended to the Board, at its meeting held on February 14, 2025. The same were thereafter approved by the Board of Directors of the Company at its meeting held on February 14, 2025. The statutory auditors of the Company have carried out limited review thereof and have issued an unmodified limited review report. 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (“Ind AS”) notified under the Companies (Indian Accounting Standards) Rule, 2015, as amended from time to time, specified under section 133 of the Companies Act, 2013. 3. The consolidated financial results of the Company have been prepared by consolidating the Company's reviewed financial results for the respective periods with the reviewed financial results of the following wholly-owned subsidiaries (“WOS”) and the Enterprises over which the Company exercises control (the Company, these subsidiaries and the enterprises hereinafter collectively referred to as “the Group”): (i) Indian WOS: Panacea Biotec Pharma Limited (“PBPL”) and Meyten Realtech Private Limited; (ii) Overseas WOS: Panacea Biotec (International) S.A., Panacea Biotec Germany GmbH and Panacea Biotec Inc. (WOS through PBPL); and (iii) Enterprises over which the Company exercises control*: PanEra Biotec Private Limited and Adveta Power Private Limited. *considered as a subsidiary for the purpose of consolidation as per Ind AS 110 4. For the nine months ended December 31, 2024, the Company has incurred loss (before tax and exceptional items) of Rs.403 lakh (nine months ended December 31, 2023: profit of Rs.556 lakh) and the Group has incurred a loss (before tax and exceptional items) of Rs.1,619 lakh (nine months ended December 31, 2023: loss of Rs.2,969 lakh). In March 2022, PBPL had sold its pharmaceutical formulations brands in India and Nepal, for a total consideration of Rs.187,200 lakh, which enabled the Group to repay its outstanding dues of Non-Convertible Debentures (NCDs) and retain sufficient surplus to fund its existing projects and operations and also helped the Group to enter new market and expediting development of new products. The surplus funds with the Group has also strengthened the working capital position, setting up new facilities for enhancement of capacities for manufacturing of vaccines drug substance and scaling up its pharmaceutical formulations business in international markets including ROW countries, USA / EU, etc. and to pursue other business opportunities. The Company has already received higher long-term business orders for vaccines from key institutional customers. Based on these measures and continuous efforts to improve the business performance, the management has prepared the financial results on a going concern basis. Multi segment 2024-04-01 2024-12-31 Unaudited Consolidated 4265600000.00 120700000.00 4386300000.00 1307500000.00 1500000.00 165600000.00 1239200000.00 28400000.00 263900000.00 1542100000.00 4548200000.00 -161900000.00 82800000.00 -79100000.00 0.00 -11800000.00 -11800000.00 0.00 -67300000.00 0.00 0.00 0.00 0.00 -67300000.00 -2500000.00 -69800000.00 -64800000.00 -2500000.00 -67300000.00 -2500000.00 61300000.00 1 -1.06 -1.06 0.00 0.00 -1.06 -1.06 Other expenses 500000000.00 Other expenses 1542100000.00 Formulations 550400000.00 Vaccines 1084500000.00 Formulations 1846200000.00 Vaccines 2419400000.00 1634900000.00 4265600000.00 0.00 0.00 1634900000.00 4265600000.00 Formulations -75800000.00 Vaccines 119600000.00 Formulations -102400000.00 Vaccines 23300000.00 43800000.00 -79100000.00 0.00 0.00 0.00 5. During the nine months ended December 31, 2024, the Group has recognised revenue of Rs.828 lakh (nine months ended December 31, 2023: Rs.3,329), out of the remaining deferred consideration of Rs.5,710 lakh (December 31, 2023: Rs.9,313 lakh) from sale of domestic pharmaceutical brands, under “Exceptional Item” in the consolidated statement of the profit and loss and the balance deferred consideration of Rs.4,882 lakh (December 31, 2023: Rs.5,984 lakh) would be recognised as revenue in subsequent quarters / years and is shown as Contract Liability. 6. The Board had, at its meeting held on November 13, 2024, approved raising of funds by way of an External Commercial Borrowing (“ECB”) of an amount upto US$ 20 million (equivalent to ~Rs.168.16 Crore) from the U.S. Government’s development finance institution, the U.S. International Development Finance Corporation (“DFC”) in relation to the construction and setting-up of additional vaccine manufacturing facility in India in order to increase the production of the Company’s hexavalent vaccine EasySix and refinancing of its existing loans availed from affiliates for the said Projects. The Due Diligence process by DFC legal counsel is in progress. 7. During the quarter under review, PBPL has made further investment of US$ 9,25,000 (~Rs.7.92 Crore) in Panacea Biotec Inc. as subscription for 9,25,00,000 shares of common stock of Panacea Biotec Inc. at a price of US$ 0.01 per share. 8. The Company publishes standalone financial results along with the consolidated financial results. In accordance with Ind AS 108, ‘Operating Segments’, the management has disclosed the segment information in the consolidated financial results. Accordingly, the segment information is given in the consolidated financial results of the Group for the quarter and nine months ended December 31, 2024. 9. The necessary certificate / report in respect of the above results in terms of requirement of Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015, has been placed before the Board of Directors. 10. Previous period amounts have been regrouped/ reclassified in compliance with Ind-AS to make them comparable with those of current period / year. 11. ‘0’ under “Rs. in Lakh” represents an amount less than Rs.50,000. Further, the figures shown in the tables may not exactly add up due to rounding off. 12. The above results are also available on the Company’s website https://www.panaceabiotec.com 0.00 43800000.00 -79100000.00 Formulations 4207000000.00 Vaccines 7908600000.00 12115600000.00 0.00 12115600000.00 Formulations 959700000.00 Vaccines 2846100000.00 3805800000.00 0.00 3805800000.00 -1100000.00 -3400000.00 -300000.00 -900000.00 0.00 0.00